Clinical Pharmacology
5 articles in this category.
Vancomycin Nephrotoxicity: Risks, Prevention, Monitoring
Vancomycin nephrotoxicity affects 5–43% of patients depending on risk factors. Learn which patients are at highest risk and how AUC-guided monitoring reduces kidney injury.
Read article
AUC/MIC Ratio: Why It Drives Vancomycin Targets
The AUC/MIC ratio explains why vancomycin efficacy depends on total drug exposure, not peak levels. Target AUC/MIC ≥400 for MRSA, here's what that means clinically.
Vancomycin for Endocarditis and Bone Infections
Vancomycin endocarditis dosing demands aggressive AUC targets and weeks of therapy. Learn duration, tissue penetration, and when to consider oral step-down or surgery.
Vancomycin TDM: When and How to Check Levels
Vancomycin therapeutic drug monitoring with AUC estimation requires knowing when to draw levels, how to interpret them, and when to bring in Bayesian software.
Vancomycin Dosing in Obese Patients: TBW vs IBW
Vancomycin dosing in obese patients depends on which body weight to use for loading and maintenance. AUC-guided TDM matters more here than in any other population.